ClinicalTrials.gg

Program

FluMist

Also written as “LAIV”, “Trivalent influenza virus vaccine live, intranasal” and “Cold-adapted influenza vaccine trivalent (CAIV-T)”.

Its studies are mostly in Influenza, Human · Neoplasms, led by 2 companies.

Furthest: phase 4, since Sep 9, 200511 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca100 open or runningphase 4since Sep 9, 2005May 27, 2005none ahead
Changchun BCHT Biotechnology11 open or runningphase 4since Apr 16, 2026Apr 16, 2026none ahead

Also a collaborator on its studies: Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2005First study: phase 1 study in NeoplasmsNew to AstraZenecaAstraZeneca · NCT00112112 · 20 enrolled · United States
  2. Aug 1, 2005Phase 3 study in Influenza, HumanAstraZeneca · NCT00125944 · 300 enrolled · United States
  3. Sep 9, 20052 phase 4 studies in Influenza, HumanAstraZeneca · NCT00192140, NCT00192218
  4. Sep 12, 20054 phase 3 studiesAstraZeneca · NCT00192491, NCT00192335, NCT00192127 and 1 more
  5. May 11, 2006Phase 3 study in HealthyAstraZeneca · NCT00325481 · 300 enrolled · United States
  6. Jun 22, 2006Phase 2 study in Influenza, HumanAstraZeneca · NCT00344305 · 200 enrolled · United States
  7. Apr 16, 2026Changchun BCHT Biotechnology's first study: phase 4 study in Influenza, HumanNew to Changchun BCHT BiotechnologyChangchun BCHT Biotechnology · NCT07545564 · 200 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A weakened live virus vaccine containing three seasonal influenza reassortants with prophylactic activity against influenza subtypes A and B. The trivalent live-attenuated influenza vaccine (LAIV) contains 2 strains of the influenza subtype A, one for H1N1 and one for H3N2, and one strain of subtype”NCIt, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07545564Influenza, Human · China4By invitationChangchun BCHT BiotechnologyApr 23, 2026200
NCT00344305Influenza, Human · United States2CompletedAstraZenecaJul 1, 2006200
NCT00325481Healthy · United States3CompletedAstraZeneca300
NCT00192413Influenza, Human · South Africa3CompletedAstraZenecaNov 20023,009
NCT00192491Influenza, Human3CompletedAstraZenecaSep 20031,200
NCT00192335Healthy · United States3CompletedAstraZeneca890
NCT00192218Influenza, Human · United States4CompletedAstraZenecaApr 20053,022
NCT00192127Influenza, Human · United States3CompletedAstraZeneca300
NCT00192140Influenza, Human · United States4CompletedAstraZenecaOct 2004345
NCT00125944Influenza, Human · United States3CompletedAstraZeneca300
NCT00112112Neoplasms · United States1CompletedAstraZenecaMar 1, 200820

How it is read

Names in the registry

  • “FluMist”, 9 entries
  • “LAIV”, 1 entry
  • “Trivalent influenza virus vaccine live, intranasal”, 1 entry
  • “Cold-adapted influenza vaccine trivalent (CAIV-T)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.